Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0088 | 0.2861 | 0.5 |
Echinococcus multilocularis | geminin | 0.0205 | 0.8662 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.8662 | 1 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0088 | 0.2861 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0098 | 0.3326 | 0.3868 |
Treponema pallidum | polypeptide deformylase (def) | 0.0231 | 0.9992 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0098 | 0.3326 | 0.3868 |
Toxoplasma gondii | hypothetical protein | 0.0231 | 0.9992 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0088 | 0.2861 | 0.5 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0088 | 0.2861 | 0.5 |
Chlamydia trachomatis | peptide deformylase | 0.0231 | 0.9992 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0088 | 0.2861 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0088 | 0.2861 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0088 | 0.2861 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0231 | 0.9992 | 0.5 |
Echinococcus granulosus | geminin | 0.0205 | 0.8662 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0067 | 0.1787 | 0.2078 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0098 | 0.3326 | 0.3868 |
Mycobacterium ulcerans | peptide deformylase | 0.0231 | 0.9992 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0231 | 0.9992 | 0.5 |
Plasmodium vivax | peptide deformylase, putative | 0.0231 | 0.9992 | 0.5 |
Trichomonas vaginalis | set domain proteins, putative | 0.0231 | 1 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0098 | 0.3326 | 0.3868 |
Brugia malayi | Pre-SET motif family protein | 0.0203 | 0.8599 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0067 | 0.1787 | 0.2078 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0203 | 0.8599 | 1 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.0231 | 0.9992 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.0231 | 0.9992 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.8662 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0067 | 0.1787 | 0.2063 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1636 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 0.2818 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.